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Abstract
 
The proteasome is the principal provider of major histocompatibility complex (MHC) class
I–presented peptides. Interferon (IFN)-
 
g
 
 induces expression of three catalytically active protea-
some subunits (LMP2, LMP7, and MECL-1) and the proteasome-associated activator PA28.
These molecules are thought to optimize the generation of MHC class I–presented peptides.
However, known information on their contribution in vivo is very limited. Here, we exam-
ined the antigen processing of two murine leukemia virus-encoded cytotoxic T lymphocyte
(CTL) epitopes in murine cell lines equipped with a tetracycline-controlled, IFN-
 
g
 
–indepen-
dent expression system. We thus were able to segregate the role of the immunosubunits from
the role of PA28. The presence of either immunosubunits or PA28 did not alter the presenta-
tion of a subdominant murine leukemia virus (MuLV)-derived CTL epitope. However, the
presentation of the immunodominant MuLV-derived epitope was markedly enhanced upon
induction of each of these two sets of genes. Thus, the IFN-
 
g
 
–inducible proteasome subunits
and PA28 can independently enhance antigen presentation of some CTL epitopes. Our data
show that tetracycline-regulated expression of PA28 increases CTL epitope generation without
affecting the 20S proteasome composition or half-life. The differential effect of these IFN-
 
g
 
–
inducible proteins on MHC class I processing may have a decisive influence on the quality of
the CTL immune response.
Key words: antigen processing • major histocompatibility complex class I • 
immunoproteasomes • PA28 • murine leukemia virus
 
Introduction
 
The presentation of peptides in MHC class I molecules is a
crucial prerequisite for effective CTL responses. The intra-
cellular processing of these peptides depends on several spe-
cialized molecules, each contributing to one of the sequen-
tial steps in class I antigen presentation. After generation of
peptides by proteolysis, the transporter associated with anti-
gen processing (TAP)
 
1
 
 molecules transport the precursor
peptides into the endoplasmic reticulum, where they can
bind to newly formed MHC class I molecules to be trans-
ported to the cell surface (for reviews see references 1, 2).
 
MHC class I–bound peptides can be considered side prod-
ucts of the continuous turnover and degradation of intra-
cellular proteins. A major proteolytic system is the protea-
some, a multicatalytic protease complex responsible for
most cytosolic protein breakdown. The proteasome has
been designated as the main provider of precursor peptides
for MHC class I presentation (3). The core 20S protea-
some is a cylindrical structure consisting of four stacked
 
rings, each containing seven homologous but distinct 
 
a
 
 or
 
b
 
 subunits. The several hydrolyzing activities are conferred
by the 
 
b
 
 subunits located in the two inner rings (for review
see reference 4).
 
1
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Independent Effect of Immunosubunits and PA28 on CTL Epitope Generation
 
The important immunomodulatory cytokine IFN-
 
g
 
,
produced during an immune response by activated T
helper lymphocytes and NK cells, enhances antigen presen-
tation by upregulation of MHC and TAP gene products as
well as proteasome subunits and regulators (5). Incubation
of vertebrate cells with IFN-
 
g
 
 alters proteasome activity
qualitatively by induction of several proteasome-associated
molecules (6), thereby recruiting this basal protein degrada-
tion system for enhanced presentation of certain immu-
nogenic peptides to the immune system. Three newly
expressed proteasome 
 
b
 
 subunits (LMP2
 
1
 
, LMP7, and
MECL-1) replace the three constitutive 
 
b
 
 subunits (in
mice: 
 
d
 
, MB-1, and MC14, respectively) in the core 20S
proteasome. After the recent identification of MC14/
MECL-1 as the third pair of proteasomal subunits (7–9),
several groups reported that these so-called immunosub-
units are incorporated interdependently. The exchange of
one subunit strongly favored the incorporation of another
(10). Transfection of LMP2 and/or LMP7 in cell lines is
known to alter cleavage specificity of 20S proteasomes (11),
predominantly leading to precursor peptides that contain
the MHC class I–presented CTL epitopes. Furthermore,
targeted deletion of LMP2 and LMP7 in mice results in
some immunodeficiency (12, 13). These findings indicate a
role for LMP7 and LMP2 in MHC class I antigen process-
ing. However, the novel findings concerning the coordi-
nated incorporation of the three immunosubunits makes it
difficult to interpret earlier studies on cleavage specificity in
which single subunits were transfected in cell lines. More
appropriately, the functional contribution of the three im-
munosubunits must be studied after expression of the joint
subunits in the absence of other IFN-
 
g
 
–inducible genes.
Besides the proteasome immunosubunits, IFN-
 
g
 
 also
regulates the expression of the proteasome-associated com-
plex PA28 (REG or the 11S regulator). PA28 was identi-
fied as a proteasome activator that strongly increases the
maximal velocity of the hydrolytic reaction and decreases
the concentration of substrate required for cleavage by pu-
rified 20S proteasomes (14, 15). Isolated PA28 does not
display any enzymatic activity by itself. Three homologous
PA28 subunits have been cloned thus far, of which only
the 
 
a
 
 and 
 
b
 
 subunits are strongly induced by IFN-
 
g
 
 (16).
Protein chemical analyses have revealed that the 
 
a
 
 and 
 
b
 
subunits form a tightly connected heterohexameric or het-
eroheptameric complex, composed of comparable amounts
of both subunits (17). Although monomers of 
 
a
 
 subunits
were shown to display some proteasome-enhancing activ-
ity, heteromultimers appeared to be more stable and effec-
tive (18). The heteromultimer is able to bind to the 
 
a
 
-rings
of the 20S core proteasome, creating bell-shaped cap struc-
tures on both ends (5). The mechanism of PA28-mediated
enhancement of the intrinsic proteasome activity is pres-
ently unknown.
PA28 was implicated in MHC class I antigen processing.
In vitro digestion studies with long peptides comprising
dominant CTL epitopes showed that purified PA28 can
enhance coordinated dual cleavages by the 20S proteasome,
leading to augmented epitope liberation (19). Furthermore,
 
expression of PA28
 
a
 
 in mouse fibroblasts increased the
sensitivity for lysis by virus-specific CTLs (20). Conflicting
data were obtained by other investigators who did not ob-
serve any effect of PA28 on antigen presentation (2). Using
PA28 
 
b
 
-subunit knockout mice, Preckel et al. (21) showed
that PA28 positively affects antigen presentation. However,
the assembly of immunoproteasomes in these mice ap-
peared to be impaired. Therefore, it was concluded that
PA28 exerts its effect indirectly via immunoproteasome
formation.
To distinguish between the effects of PA28 and that of
immunoproteasomes, we generated murine cell lines with
tightly controlled expression either of the three immu-
nosubunits or of PA28
 
a
 
 and 
 
b
 
. By using well-defined
CTL clones directed against two murine leukemia virus
(MuLV)-derived peptides, we show that the presentation
of the immunodominant gag-leader epitope is enhanced by
the presence of immunosubunits as well as by PA28. Im-
portantly, the effect of PA28 was exerted in the absence of
immunosubunits. The presentation of the subdominant
epitope was not affected. Our results supply strong evi-
dence for an independent but differential role of these pro-
teasome-related molecules in the generation of CTL
epitopes.
 
Materials and Methods
 
Cell Lines and Mice.
 
All cell lines are derived from C57BL/6
(B6, H-2
 
b
 
) mice. RMA and TAP2 mutant RMA-S cells are
Rauscher MuLV–induced lymphomas. The TAP1 and TAP2
transfectants of RMA-S (rat mtp1
 
a
 
 and rat mtp2
 
a
 
, respectively)
have been described previously (22). Transfected mouse embryo
cell (MEC) lines were derived from a primary culture of embry-
onic cells of a B6 mouse deficient for p53. LPS blasts were ob-
tained by culturing spleen cells for 3 d with 10 
 
m
 
g/ml LPS
(
 
Escherichia coli
 
 0111:B4, Difco Laboratories). Ficolled cells were
washed and used as targets in CTL assays. The env-specific CTL
clone 10B6, generated against Moloney MuLV in a B6.CH-2
 
bm13
 
mouse, recognizes the SSWDFITV epitope presented by H-2K
 
b
 
(env; amino acids 189–196) as previously described (23). H-2D
 
b
 
–
restricted CTL clone 1 specific for the gag-leader peptide
(CCLCLTVFL; amino acids 75–83) was generated against Molo-
ney MuLV in a B6 mouse, as previously described (24). All cell
lines were cultured in Iscove’s modified Dulbecco’s medium
(Biowhittaker Europe), supplemented with 8% heat-inactivated
FCS (GIBCO BRL), 2 mM L-glutamine (ICN Biomedicals), 100
IU/ml penicillin (Yamanouchi Pharma), and 30 
 
m
 
M 2-ME
(Merck) at 37
 
8
 
C in humidified air with 5% CO
 
2
 
.
B6 mice were bred under specific pathogen–free conditions in
the TNO-PG breeding facility. TAP
 
2/2
 
 mice were purchased
from The Jackson Laboratory (B6/129 TAP
 
2/2
 
).
 
DNA Constructs and Generation of Transfectant Cell Lines.
 
The
eukaryotic expression plasmids pTET-splice and pTET-tTAk,
containing the tetracycline-regulated transcription activator tTAk,
have been described elsewhere (25). Generation of the MEC217
cells expressing inducible levels of the cDNAs of murine (H-2
 
b
 
haplotype) LMP2, LMP7, and MECL-1 was described recently
(26). cDNAs of the murine PA28
 
a
 
 and 
 
b
 
 (H-2
 
b
 
 haplotype) were
cloned into the EcoRI/EcoRI and SalI/EcoRV sites of the
pTET splice vector using standard procedures. The PA28
 
ab
 
transfected cells were established by calcium-phosphate precipita- 
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tion. In brief, 7.5 
 
3
 
 10
 
5
 
 MEC/tTAk cells (clone 29) were
plated in 10-cm dishes, transfected with a plasmid mixture con-
sisting of 10 
 
m
 
g pTET-PA28
 
a
 
, 10 
 
m
 
g pTET-PA28
 
b
 
, and 4 
 
m
 
g
pLXSP which confers resistance to puromycin, and then diluted
in 96-well plates in medium containing 5 
 
m
 
g/ml puromycin, 200
 
m
 
g/ml hygromycin B (Merck), and 400 ng/ml tetracycline
(Sigma-Aldrich). Growing clones were screened for expression
of PA28
 
a
 
 and PA28
 
b
 
 by immunoblot analysis using specific an-
tisera.
 
Isolation of PA28 Complexes.
 
To isolate PA28 complexes, the
pellets of 2 
 
3
 
 10
 
7
 
 MEC-PA28 cells grown in the absence or pres-
ence of tetracycline for 3 d were lysed in 800 
 
m
 
l of lysis buffer
(0.1% Triton X-100, 50 mM Tris-HCl, 5 mM MgCl
 
2
 
, and 1 mM
EDTA [pH 7.5]) without protease inhibitors. Cell lysates were
freeze-thawed three times and then applied to a 10–40% glycerol
gradient that was centrifuged for 16 h at 40,000 rpm in a Sorvall
ultracentrifuge. Gradient fractions of 600 
 
m
 
l were collected and
tested for the presence of PA28 by Western blot analyses using
PA28
 
a
 
- and PA28
 
b
 
-specific polyclonal rabbit antisera (10, 27).
To determine PA28 activity, 20 
 
m
 
l of the glycerol gradient
fractions and 80 
 
m
 
l of assay buffer (50 mM Tris-HCl [pH 7.5], 25
mM KCl, 10 mM NaCl, 1 mM dithiothreitol, and 0.1 mM
EDTA) containing 100 
 
m
 
M Suc-LLVY-AMC were incubated in
96-well plates. To each well, 30 ng of 20S proteasomes of non-
transfected MECs were added and the reactions were incubated
for 1 h at 37
 
8
 
C. Fluorescence emission was measured at 460 nm
(excitation 355 nm) with a Fluorostar reader.
 
Isolation of Cellular 20S Proteasomes and Western Blot Analysis.
 
Proteasomes were purified from MEC217 cells cultured in the
absence or presence of tetracycline (10 ng/ml and 400 ng/ml) as
previously described (26). Protein content in the samples was
quantified at an OD of 280 nm. 200 ng of material was separated
on 12% SDS polyacrylamide gels and electrophoretically trans-
ferred to nitrocellulose membranes. Blots were incubated for 1 h
in 10% horse serum/5% (wt/vol) lowfat dry milk/0.4% Tween-
20 in PBS and then probed overnight with polyclonal mouse
LMP2-, 
 
d
 
-, MECL-1–, MC14-, LMP7-, MB1-, and MC3-spe-
cific rabbit antisera at a 1:1,000 dilution in 2% dry milk/0.1%
Tween-20 in PBS. Filters were incubated with horseradish per-
oxidase–conjugated anti–rabbit IgG and developed by enhanced
chemiluminescence (Boehringer Mannheim).
 
Metabolic Labeling, Immunoprecipitation, and Gel Analyses.
 
A to-
tal of 2.5 
 
3 
 
10
 
5
 
 MEC-PA28 cells were cultured with 400 ng/ml
tetracycline or without tetracycline, pulse-labeled for 1 h with
150–300 
 
m
 
Ci/ml translabel [
 
35
 
S]methionine, and then chased for
different time intervals. Cells were harvested in 1% NP-40 lysis
buffer with protease inhibitors and the lysates were cleared by cen-
trifugation for 8 min at 14,000 rpm. 20S proteasomes and PA28
 
a
 
were immunoprecipitated from the lysates using rabbit anti-20S or
anti-PA28
 
a
 
 antisera and analyzed by SDS-PAGE or by two di-
mensional NEPHGE/SDS-PAGE, as previously described (26).
Gels were exposed for autoradiography. Radioactive signals were
quantified using a Molecular Dynamics phosphorImager.
 
Moloney MuLV Infections.
 
Abelson Moloney virus was de-
rived from NIH/3T3 Abelson virus nonproducer cells (ANN-1),
which were productively infected with cloned Moloney MuLV
(28). Batches of virus containing supernatants were collected after
24 h and stored at 
 
2
 
80
 
8
 
C.
All MEC lines were infected with Abelson Moloney MuLV by
culturing for 3–4 d in complete culture medium, containing 50%
(vol/vol) virus-containing supernatant with 10 
 
m
 
g/ml polybrene
(Sigma-Aldrich). Expression of viral genes was determined by
flow cytometry using rabbit FITC-conjugated anti–Moloney
 
MuLV antiserum. Titrated concentrations of tetracycline were
added, starting 1 d before virus infection.
 
CTL Activation Assays.
 
Cytolytic activity of CTL clones was
measured and calculated by 
 
51
 
Cr-release assays, as previously de-
scribed (24). IFN-
 
g
 
 release by CTLs was measured in U-bottom
plates (Costar) using 8 
 
3
 
 10
 
3
 
 CTLs incubated with indicated
amounts of stimulator cells in the presence of recombinant human
IL-2 (5 Cetus units/ml; Eurocetus). Supernatants were harvested
after 8–18 h and IFN-
 
g
 
 content was measured by sandwich
ELISA technique using anti–mouse IFN-
 
g
 
–specific antibodies
(clones XMG1.2 and biotinylated R4-6A2; PharMingen), as pre-
viously described (29).
 
Treatment with Proteasome Inhibitors.
 
Moloney MuLV–infected
target cells were treated with the proteasome inhibitors lactacystin
or NLVS (4-hydroxy-5-iodo-3-nitrophenylacetyl-leu-leu-leu-
vinylsulfone; NIP-L
 
3
 
VS; Calbiochem) before incubation with
CTLs. 1–2 
 
3
 
 10
 
6
 
 cells were incubated with 20 
 
m
 
M lactacystin
(Calbiochem) or 20 
 
m
 
M NLVS at 37
 
8
 
C for 4 h. Treatment with
proteasome inhibitors did not influence expression of Moloney
MuLV–encoded proteins in virus-infected cells, as determined
with MuLV-specific antibodies. To control the viability of treated
target cells, synthetic peptides (1 
 
m
 
g/ml) were added during the
last 30 min of the 4-h incubation period. Inhibitor and unbound
peptide were removed by extensive washing before incubation
with CTLs.
 
Results
 
Processing of the gagL-derived Epitope is TAP and Proteasome
Dependent.
 
The role of the immunosubunits LMP2,
LMP7, and MECL-1 and of the proteasome regulator
PA28 in processing of MHC class I–presented peptides was
studied using the well-defined Moloney MuLV system in
B6 mice. Two Moloney MuLV–derived CTL epitopes
have been described: the immunodominant D
 
b
 
-binding
gag-leader (gagL)–derived peptide CCLCLTVFL (30) and
the subdominant K
 
b
 
-binding gp75-env–derived peptide
SSWDFITV (23). In earlier studies we have shown that the
presentation of the env-derived epitope depends on the
function of TAP (31) and proteasomes (29). The gagL pep-
tide needs to be liberated from the leader sequence of the
gag-Pr75 protein. In Moloney MuLV, this leader encodes
88 amino acids and serves to directly translocate the Pr75
precursor protein into the endoplasmic reticulum (32).
Here, we examined the necessity of TAP for presentation
of the gagL-derived epitope, making use of the TAP2 mu-
tant cell line RMA-S, which lacks a functional TAP1,2
heterodimer. The wild-type RMA and the mutant RMA-S
cell lines both express the gag-Pr75 protein. These cell
lines were tested for recognition by the gagL-specific CTL
clone in a chromium cytotoxicity assay. RMA-S cells were
not sensitive to lysis, whereas RMA cells were killed to a
high level (Fig. 1 A). Stable transfectants of RMA-S with
the rat TAP1 or TAP2 cDNA showed that only trans-
fection of the TAP2 gene resulted in restored sensitivity
for lysis by the gagL-specific CTLs. In addition, LPS
blasts from wild-type B6 and TAP1
 
2/2 mice were infected
with Moloney MuLV and tested for recognition by
gagL-specific CTLs. Secretion of IFN-g by the gagL-spe-
cific CTLs was markedly lower upon incubation with in-486 Independent Effect of Immunosubunits and PA28 on CTL Epitope Generation
fected TAP12/2 LPS blasts when compared with infected
wild-type LPS blasts (Fig. 1 B), indicating that at least the
majority of the gagL peptides need to be transported by
TAP before reaching the cell membrane. Also the env-spe-
cific CTLs selectively recognized Moloney MuLV–infected
wild-type cells (Fig. 1 C).
To investigate the role of proteasomes in the generation
of the gagL-derived peptide, we used the proteasome-spe-
cific inhibitors lactacystin and vinyl sulfone NLVS. MECs
from B6 mice were infected with Moloney MuLV, result-
ing in recognition by the gagL-specific CTL clone (Fig. 2
A). Preincubation of the infected MECs with the protea-
some-specific inhibitors completely abrogated recognition
of Moloney-infected target cells by the gagL-specific CTL
(Fig. 2 A) and env-specific CTL (data not shown) (29).
These inhibitor-treated targets were still able to present
synthetic peptide to the CTLs (Fig. 2 B). Thus, the presen-
tation of the CTL epitope from the leader of gag requires
functional proteasomes as well as TAP heterodimers.
Enhanced In Vivo Generation of gagL- but not env-derived
Peptide by Immunoproteasomes. The enzymatic activity of
20S proteasomes is mediated by three different b-subunits,
d (or b1), MB1 (or b5), and MC14 (or b2), which are ex-
changed for the so-called immunosubunits, LMP2 (in-
duced  b1; ib1), LMP7 (ib5), and MECL-1 (ib2), respec-
tively, after treatment with IFN-g. However, IFN-g
induces a wide variety of proteins involved in MHC class I
and class II antigen presentation, including additional pro-
teasome-associated regulatory proteins. To investigate the
role of the three proteasome immunosubunits, we used an
MEC line (MEC217) with coordinated expression of the
murine cDNAs encoding LMP2, LMP7, and MECL-1
driven by a strong tetracycline-regulated promoter (26).
When cultured in the presence of high concentrations of
tetracycline (400–1,000 ng/ml), these cells express protea-
somes with constitutive subunits, comparable to untrans-
fected MECs (data not shown). Lower doses of tetracycline
allow defined expression levels of the introduced cDNAs,
resulting in a gradual replacement of the constitutive sub-
units d, MC14, and MB1 by the immunosubunits LMP2,
MECL-1, and LMP7, respectively (Fig. 3). Probing of the
a-subunit MC3 showed that equal amounts of 20S protea-
somes were loaded in each lane (Fig. 3). Using this system
we are able to uncouple the effects of the replacement of
the immunosubunits from the multiple IFN-g effects in
vivo.
Using these LMP2-, LMP7-, and MECL-1–transfected
MEC217 cells, we tested the efficiency of env- and gagL-
derived CTL epitope generation in relation to immuno-
subunit expression. MEC217 cells were infected with
Abelson Moloney virus and cultured in the absence or
presence of two concentrations of tetracycline. After 3–4 d,
these cells were harvested and used as targets for gagL- and
env-specific CTLs in an IFN-g release assay. As shown in
Figure 1. TAP-dependent presentation of MuLV gagL-derived CTL epitope. (A) Cytolytic activity of a gagL-specific CTL clone against Rauscher
MuLV–induced RMA lymphoma and TAP2-mutant RMA-S lymphoma cell lines. RMA-S cells stably transfected with rat cDNA of TAP1 (mtp1a) or
TAP2 (mtp2a) are indicated as RMA-S.rTAP1 and RMA-S.rTAP2, respectively. CTLs were incubated for 4 h with Cr-labeled target cells at the effector
to target ratio as depicted (x-axis). Error bars represent standard deviation of triplicate wells. One representative experiment out of three is shown. j,
RMA; s, RMA-S; ., RMA-S.rTAP1; m, RMA-S.rTAP2. LPS blasts derived from wild-type B6 and TAP12/2 spleen cells were infected with Molo-
ney MuLV and incubated with gagL-specific (B) and env-specific (C) CTL clones. 4 3 104 LPS blasts (black bars) and 2 3 104 LPS blasts (gray bars) were
incubated with a constant number of CTLs (8 3 103). After 18 h, IFN-g release was measured with ELISA technique and OD at 415 nm is shown. Rec-
ognition of LPS blasts exogenously loaded with synthetic gagL peptide (CCLCLTVFL; 1 mg/ml) is shown in D. Similar results were obtained in an ad-
ditional experiment. The means of triplicate wells and the standard deviations are shown.487 van Hall et al.
Fig. 4 B, env-specific CTLs incubated with induced or
noninduced MEC217 cells released intermediate and com-
parable amounts of IFN-g, indicating that expression of the
immunosubunits did not alter the stimulatory capacity of
these cells. Remarkably, the culture of infected MEC217
cells with diminishing concentrations of tetracycline re-
sulted in strongly increased recognition by the gagL-spe-
cific CTLs (Fig. 4 A). Since the CTL response was mark-
edly enhanced towards targets with induced expression of
the immunosubunits, we concluded that “immunoprotea-
somes” processed the gagL peptide more efficiently than
did constitutive proteasomes. The expression level of cell
surface MHC class I molecules was not detectably increased
in the induced cells, as measured by flow cytometry. Fur-
thermore, all MEC217 transfectants were equally well rec-
ognized by CTLs when exogenously loaded with synthetic
peptide, indicating comparable peptide-presenting capaci-
ties (data not shown). Treatment of the induced MEC217
cells with the proteasome inhibitors lactacystin or NLVS
resulted in strongly impaired CTL recognition, which
could again be recovered by exogenous loading with syn-
thetic peptide (Fig. 4 C).
Several control experiments demonstrated that the ob-
served increased recognition could be attributed entirely to
the induced immunosubunits. First, a role for tetracycline
or the tTAk transcription activator in peptide processing
was excluded by testing Moloney-infected control transfec-
tants (data not shown). In addition, immunofluorescence
studies with MuLV-specific antibodies showed equal ex-
pression levels of viral gag and env proteins on induced and
noninduced cells, indicating that the different target cell
populations were infected with the same efficiencies (data
not shown). In conclusion, the exchange of immunosub-
units in the proteasome strongly increased the presentation
of the gagL-epitope, but not the env-derived CTL epitope.
Controlled Expression of Functional PA28a/b Complexes
Does Not Alter 20S Proteasome Composition. Using the same
tetracycline-regulated expression system, we have generated
MEC transfectants containing the murine cDNAs of PA28a
and b. When these cells were cultured with high concentra-
tions of tetracycline (400–1,000 ng/ml), very low levels of
endogenous PA28a and b proteins were detected, compa-
rable to the levels in control transfectants containing the
regulatory tTAk encoding plasmid only. After withdrawal of
tetracycline, the PA28a and b proteins were strongly up-
regulated within a few hours, as tested by metabolic label-
ing. High and stable expression levels were reached after
8–24 h of culture in the absence of tetracycline (data not
shown).
To study if the induction of the PA28a and b subunits
led to the formation of functional activation complexes, we
isolated PA28 from MEC-PA28 cells that were cultured for
Figure 2. Proteasome-mediated processing of
the MuLV gagL epitope. Moloney MuLV infected
B6 MEC line was treated with the proteasome in-
hibitors lactacystin (20 mM) or NLVS (20 mM) for
4 h. After extensive washing, 2 3 104 (black bars)
or 5 3 103 target (stippled bars) cells were incu-
bated with the gagL-specific CTL clone (8 3 103)
for 8 h (A). Targets were loaded with synthetic
peptide during the last 30 min of the treatment
with inhibitors to test the peptide-presenting ca-
pacity of treated target cells (B). IFN-g release was
measured with ELISA. One representative experi-
ment out of three is shown. Bars represent mean
values of triplicate wells 6 SD.
Figure 3. Tetracycline-controlled exchange of constitutive subunits for
immunosubunits in 20S proteasomes of MEC217 cells. 20S proteasomes
were isolated from MEC217 cells that were cultured in the absence or
presence of 10 ng/ml or 400 ng/ml tetracycline for 3 d. 200 ng of puri-
fied 20S proteasomes were separated by SDS-PAGE and probed with
polyclonal rabbit antisera specific for the immunosubunits LMP2,
MECL-1, and LMP7, for the constitutive b-subunits d, MC14, and MB1
and for the a-subunit MC3, as indicated. n.d., not determined.488 Independent Effect of Immunosubunits and PA28 on CTL Epitope Generation
3 d with high concentrations (500 ng/ml) of tetracycline or
without tetracycline. Lysates of these cells were separated
on a glycerol gradient and fractions of 600 ml were col-
lected and assayed for the presence of PA28 by immuno-
blot analysis. After this protocol, assembled PA28 complexes
are expected to migrate in fractions 7–10 of the glycerol
gradient. In the noninduced cells, PA28b was undetectable
and only low levels of PA28a were detected (Fig. 5, A and
B), indicating low expression levels of endogenous PA28 in
B6 MECs. In contrast, strong signals for PA28a and b
were found in fractions 7–10 of induced MEC-PA28 cells,
showing induced expression of PA28 and proper assembly
into hexa- or heptameric complexes (Fig. 5, A and B). The
PA28 that is present in the early fractions most likely con-
sists of nonassembled single subunits.
The activity of the PA28-containing fractions was estab-
lished by measuring the capacity to enhance the 20S pro-
teasome-mediated cleavage of the Suc-LLVY-AMC sub-
strate. As expected, in the absence of 20S particles, the
PA28-containing fractions (7–10) did not show any enzy-
matic activity (Fig. 5 D). However, when low amounts of
purified constitutive 20S proteasomes were added to each
fraction, a clear enhancement of substrate conversion was
observed in the presence of fractions that contained multi-
meric PA28 (Fig. 5 C). The same glycerol fractions of non-
induced MEC-PA28 cells were markedly less efficient in
enhancing 20S activity. The enzymatic conversion that was
observed in the higher fractions was probably due to the
presence of isolated endogenous 20S, 26S, or even PA28-
capped 20S proteasomes (fractions 12–20; reference 33).
Thus, the presence of PA28 strongly enhances the hydroly-
sis of the Suc-LLVY-AMC substrate, showing that PA28
induced in our MEC-PA28 transfectant is functional.
Recently, PA28 was postulated to be crucially involved
in the assembly of immunoproteasomes (21). To examine
the potential effects of PA28 on proteasome subunit com-
position in our MEC-PA28 transfectant, induced and non-
induced MEC-PA28 cells were metabolically labeled and
20S complexes were immunoprecipitated (Fig. 6). Two-
dimensional gel analysis revealed that 20S proteasomes of
both PA28-induced and noninduced cells contained the
constitutive b-subunits (d and MB1), but lacked the im-
munosubunits (LMP2, LMP7, and MECL-1), indicating
the sole formation of constitutive proteasomes in these cells
(Fig. 6 A). Furthermore, pulse–chase analyses showed that
PA28 affected neither 20S proteasome half-life (Fig. 6 B)
nor the total amount of 20S proteasomes, as evident from
the comparison of the obtained radioactive signals with
those of an immunoprecipitated cellular protein (data not
shown). Thus, expression of PA28a/b complexes does not
alter the quality or quantity of 20S proteasomes in MEC-
PA28 cells. In conclusion, the tetracycline-inducible system
enables us to exclusively study the role of PA28 on CTL
epitope presentation in the absence of other changes in the
proteasome.
Expression of PA28a/b Enhances Presentation of gagL- but
not of env-derived CTL Epitopes. To examine the effect of
PA28a/b on presentation of the MuLV-encoded CTL
epitopes, we used Abelson Moloney virus–infected MEC-
PA28 cells in CTL activation assays. Virus-infected MEC-
Figure 4. Expression of the immunosubunits enhances presentation of the MuLV gagL, but not the env CTL epitope. The mouse embryo cell line
MEC217 containing the inducible immunosubunits LMP2, LMP7, and MECL-1 was infected with Moloney MuLV and cultured with decreasing con-
centrations of tetracycline for 3 d. Infected and noninfected control cells were harvested and used as targets (2 3 104 cells) with gagL-specific (A) and
env-specific (B) CTL clones. IFN-g release after 9 h of incubation is shown. Mean values of duplicate wells are shown. Moloney MuLV–infected
MEC217 cells cultured for 3 d without tetracycline to induce the incorporation of the immunosubunits were treated for 4 h with 20 mM proteasome in-
hibitor lactacystin (C). Targets cells were extensively washed and 2 3 104 (black bars) or 1 3 104 (stippled bars) cells were incubated with gagL-specific
CTL (8 3 103). Representative example of four different experiments with similar outcomes is shown. Mean values of triplicate wells 6 SD are shown.489 van Hall et al.
PA28 cells were cultured for 3–4 d in the presence or ab-
sence of tetracycline. As shown in Fig. 7 A, the recognition
of induced cells by the gagL-specific CTL clone was mark-
edly higher than recognition of noninduced cells. Three
independent experiments showed that optimal expression
of PA28 increased the MHC class I presentation of the
gagL peptide between 60 and 100%. Suboptimal induction
at intermediate tetracycline concentrations (10 ng/ml) re-
sulted in intermediate CTL activation (Fig. 7 A). Analysis
of other secreted cytokines, such as TNF-a, reflected the
results obtained for IFN-g. Importantly, the addition of
IFN-g–neutralizing antibodies during the assay did not al-
ter the obtained results, indicating that the IFN-g pro-
duced by the CTLs did not influence the presentation of
the epitope (data not shown). In contrast to the gagL pep-
tide, presentation of the env-derived CTL epitope was not
influenced by the presence of PA28 (Fig. 7 B). Since we
found that the response of the env-specific CTLs was also
not increased after induction of the immunosubunits (Fig. 4),
we performed control experiments to exclude the possibility
that the initial amount of presented env-peptide was already
saturating for the CTL clone. Addition of a small number
of peptide-loaded target cells to Moloney-infected targets
strongly increased the IFN-g responses of the CTLs, indicat-
ing that the presented amounts of env-peptide in Moloney-
infected cells was not saturating (data not shown).
To establish whether the stimulating effect of PA28 on
the epitope generation was mediated via the proteasome,
Figure 5. Tetracycline-regulated expression and function of PA28a
and b proteins in the MEC-PA28 B6 cell line. Cell lysates of MEC-PA28
cells that were cultured for 3 d in the absence (2 TET) or presence (1
TET) of 400 ng/ml tetracycline were centrifuged on a glycerol gradient
(10–40%) and collected as 600 ml fractions. Samples of 25 ml of each frac-
tion were separated by SDS-PAGE, blotted onto nitrocellulose and
probed with specific antibodies to detect the PA28 a (A) and PA28 b (B)
proteins. Fractionated cell lysates of MEC-PA28 cells were subsequently
tested for proteasome activating capacity in a peptide hydrolysis assay us-
ing Suc-LLVY-AMC as a substrate. Of each glycerol fraction, 20 ml were
mixed with 100 mM substrate in assay buffer and incubated in the pres-
ence (C) or absence (D) of 30 ng purified 20S proteasomes. Hydrolyzing
activity is shown for fractions isolated from noninduced cells, cultured in
the presence of 400 ng/ml tetracycline (open symbols) and for fractions
from induced cells, cultured in the absence of tetracycline for 3 d (closed
symbols). Release of the fluorescent AMC-group was detected at an
emission wavelength (Em) of 460 nm using a spectrofluorometer. Mean
values of duplicate wells are shown.490 Independent Effect of Immunosubunits and PA28 on CTL Epitope Generation
we inhibited the proteasome by preincubation with lacta-
cystin. In this independent experiment, lactacystin treat-
ment rendered the MEC-PA28 cells completely unstimula-
tory for the gagL-specific CTL and the env-specific CTL
(Fig. 8, A and B). This indicated that the stimulating effect
of PA28 on the presentation of the gagL-epitope is medi-
ated via the proteasome and that this effect is completely
dependent on functional proteasome activity. The tetracy-
cline-regulated expression of both PA28a and b genes has
enabled us to selectively address the role of PA28 on the
processing of CTL epitopes, independently of other IFN-
g–inducible proteins. These data suggest that PA28 associ-
ates with constitutive proteasomes in a functional way,
leading to increased CTL epitope generation.
In conclusion, we show evidence for involvement of the
proteasome-activator PA28 in the generation of a naturally
processed CTL epitope. Induction of PA28 as well as the
proteasome immunosubunits enhanced the presentation of
the gagL peptide, showing that these IFN-g–inducible
genes contribute to improved generation of this immu-
nodominant CTL epitope in vivo.
Discussion
Here, we provide evidence for a differential role of both
the proteasome-associated immunosubunits and the PA28
activator on the generation of virally encoded CTL
epitopes. Although a strong augmentation in epitope pro-
cessing was determined for one Moloney MuLV–derived
CTL epitope, the generation of another Moloney-derived
epitope was not influenced by induction of the immuno-
subunits or PA28 in the same infected cell. Using a tetracy-
cline-regulated transfection system, the expression of
LMP2, LMP7, and MECL-1 in one cell line and PA28a
Figure 6. PA28 does not influence 20S proteasome subunit composition or stability. MEC-PA28 cells were cultured in the presence (400 ng/ml) or ab-
sence of tetracycline, pulsed with [35S]methionine, and chased for 8 h (A). 20S proteasomes were immunoprecipitated from the detergent lysates and subjected
to two-dimensional gel electrophoresis. In B, labeled MEC-PA28 cells were chased for 0, 24, and 48 h. 20S proteasomes and PA28a were immunoprecipi-
tated and separated by SDS-PAGE. Molecular weight markers in kD are indicated on the right. Signals at t 5 0 h represent 20S precursor subunits (top).
Figure 7. Induction of PA28 selectively
increases the presentation of the gagL-derived
epitope. Moloney MuLV–infected MEC-
PA28 cells were cultured with decreasing
concentrations of tetracycline for 3 d and
used as targets (2 3 104) with gagL-specific
(A) and env-specific (B) CTLs (8 3 103).
IFN-g release by the CTLs was measured
after 9 h. Similar results were obtained in
two additional experiments (see also Fig. 7).
The mean of duplicate values is shown.491 van Hall et al.
and b in another could be tightly regulated by concentra-
tions of tetracycline in the culture medium. This enabled
us to study the effect of these IFN-g–inducible proteins in-
dependently of other IFN-g–mediated effects. These data
suggest that immunosubunits and PA28 increase the pre-
sentation of certain but not all CTL epitopes. This, to-
gether with the fact that a basal level of epitope presenta-
tion was detected in the absence of these molecules,
supports the idea that immunosubunits and PA28 are not
essential for MHC class I antigen processing in general (34,
35). Rather, subtle changes in cleavage fine specificity or
accelerated peptide generation seem to be the major role
for the studied IFN-g–inducible proteasome-related pro-
teins.
Interestingly, the immunosubunits and PA28 only af-
fected the generation of the immunodominant gagL-derived
epitope and not the subdominant env-epitope. Next to
other factors, proteasome-mediated proteolysis of MHC
class I–presented peptides has been shown to influence the
hierarchy of OVA peptide–specific T cell responses (36).
The subdominant env-derived CTL epitope binds to
H-2Kb with high affinity (23), is efficiently translocated by
TAP (37), and has a COOH terminus that is properly
cleaved by proteasomes (29). Still, the CTL response to-
wards this peptide in B6 mice is inferior to the response to-
wards the gagL epitope (23). We now observe a correlation
between the subdominance of the env-derived CTL epitope
and its failure to show increased peptide presentation after
induction of either immunosubunits or PA28.
Our findings that the processing of a leader-encoded
epitope is dependent on TAP and proteasome were rather
unexpected. Apparently, gagL precursor peptides are even-
tually derived from the cytosol, although the gag-Pr75
molecule, most likely carrying the leader as the transmem-
brane region, is naturally routed to the cell surface. Alter-
natively, gagL-epitopes may derive from misfolded gag-
Pr75 proteins that are reimported from the endoplasmic
reticulum to the cytosol and are targeted for rapid degrada-
tion by proteasomes (38). TAP and proteasome-dependent
processing were also observed for the Db-restricted CTL
epitope gp33 of lymphocytic choriomeningitis virus (LCMV)
that is encoded on the leader of gp (39, 40). These findings
show that leader-derived epitopes can be processed by clas-
sical MHC class I processing routes.
Recently, several groups have shown that under phys-
iological conditions the three catalytic subunits LMP2,
LMP7, and MECL-1 are exchanged coordinately for the
constitutive b subunits in proteasomes. Since the third pair
of IFN-g–regulated subunits MECL-1/MC14 was only re-
cently identified, most studies have not evaluated the role
of the three immunosubunits together. Moreover, docu-
mentation on the effect of immunosubunits on the genera-
tion of CTL epitopes in vivo is very limited. Next to the
gagL-peptide of Moloney MuLV we also observed im-
proved presentation of an Adenovirus type 5 E1B-derived
CTL epitope due to induced expression of immunoprotea-
somes in our tetracycline-regulated MECs (26). Strikingly,
in the same experiments no differences were detected in
the presentation of a CTL epitope from the Adenovirus
E1A-protein (Sijts, A., and P.-M. Kloetzel, unpublished
observations). In addition, we recently showed that the
hepatitis B virus core antigen–derived HBcAg141-151
Figure 8. Enhanced CTL epitope presentation by PA28 is proteasome dependent. Moloney MuLV–infected MEC-PA28 cells were treated with the pro-
teasome inhibitor lactacystin (20 mM) for 4 h. Treated cells were incubated with MuLV gagL-specific (A) and env-specific (B) CTL clones (8 3 103), and
IFN-g release was measured after 18 h. Black bars represent 4 3 104 targets and stippled bars represent 2 3 104 targets. The mean of triplicates 6 SD is depicted.492 Independent Effect of Immunosubunits and PA28 on CTL Epitope Generation
epitope is produced by immunoproteasomes but not by
constitutive proteasomes. Consequently, this epitope was
only presented after IFN-g–induced expression of immu-
nosubunits (41). Thus, these data indicate that immunopro-
teasomes promote the generation of some MHC class I–pre-
sented peptides that are poorly generated otherwise. The
recent insight in the interdependent incorporation of the
three immunosubunits validated the evaluation of single
LMP2- and LMP7-deficient mice, because both knockout
mice lack immunoproteasomes. These mice displayed im-
paired presentation of influenza NP peptide and HY anti-
gen, respectively, whereas no influence was found on the
presentation of the OVA-derived peptide (12, 13).
The role of PA28 in antigen processing is currently de-
bated. Although it was originally described as a potential
and strong activator of the proteasome in peptide digestion
studies, only one study showed some influence of PA28a
on the generation of two viral peptides in vivo (20). In ad-
dition, we show the importance of PA28 in the generation
of some, but not all, CTL epitopes, such as the Moloney
MuLV env epitope. In summary, these data on the effects
of the IFN-g–inducible molecules on peptide presentation
are observed in several distinct antigenic systems and con-
firm the interpretation of the results presented here. Impor-
tantly, the current study unequivocally documents for the
first time independent enhancement of CTL epitope pre-
sentation by either the LMP2, LMP7, and MECL-1 sub-
units, or by the PA28a/b molecules.
A recent study suggests that the action of the PA28a/b
complex resides in the induced assembly of immunoprotea-
somes (42). However, our experiments indicate that PA28
has a separate, distinct mode of action in conjuncture with
constitutive proteasomes, independent of immunoprotea-
somes. Intriguing questions remain, in particular how the
immunosubunits and PA28 facilitate the presentation of
peptides and what mechanism underlies the differential en-
hancement in peptide presentation. The presence of im-
munosubunits might lead to altered cleavage site specificity,
depending on the primary amino acid sequence of the sub-
strate and thus may produce MHC class I ligands that are
not produced otherwise. However, as with the peptides
shown here and probably the majority of epitopes, MHC
class I ligands are generated already in the absence of im-
munosubunits at different efficiencies. Thus, in the case of
the gagL-derived epitope analyzed here, it appears that the
immunosubunits do not change the specificity of the cleav-
age sites used, but rather the cleavage site preference of the
proteasome (6), resulting in improved liberation of the
epitope from the substrate. The differential effect observed
for our epitopes may be explained by the different se-
quence characteristics of the epitopes, including differences
in flanking residues and within the epitopes themselves.
In our transfected MEC line, PA28 associates with con-
stitutive proteasomes. In IFN-g–treated cells, one would
expect PA28 to associate with both immunoproteasomes
and constitutive proteasomes due to the presence of a
mixed population of proteasomes. However, in vitro data
have shown that PA28 exerts the same effects on both types
of proteasomes (Kuckelkorn, U., and P.-M. Kloetzel, per-
sonal communication). For a number of substrates it has
been shown in vitro that PA28 enhances the generation of
peptides that are the products of two consecutive endopro-
teolytic cleavage events (19), possibly due to enhanced pro-
teasomal activity. Although PA28 enhances proteasome ac-
tivity in vitro, there is no evidence that the expression of
PA28 alters the turnover of cellular proteins (20) and thus it
appears unlikely that the PA28-mediated effect is due to in-
creased substrate turnover. Indeed, an increase in dual
cleavage events would also occur if a substrate is retained
longer with the proteasome barrel before release. There-
fore, PA28 may control the exit of an antigenic product.
Since most proteins in the cell are turned over via the
26S proteasome complex, the ubiquitin-26S proteasome
system is most likely rate limiting with regard to the turn-
over rate of a given substrate. This raises the question con-
cerning the connection between the PA28-20S proteasome
system and the PA700-proteasome (26S proteasome) sys-
tem within the cell. Based on the recent observation by
Hendil et al. (42), we would presently favor a model that
combines the ubiquitin-proteasome system and PA28, sug-
gesting that upon induction of PA28 synthesis, PA700–20S
immunoproteasome–PA28 complexes are formed. Such a
complex would allow the ubiquitin-dependent, rate-con-
trolled turnover of proteins and at the same time guarantee
the efficient generation of MHC class I ligands.
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